Generic Medicine Info
Depression; pulmonary insufficiency; sleep apnoea; preexisting CNS depression or coma; severe hepatic impairment. Porphyria. Pregnancy and lactation. Elderly and debilitated patients; young adults and children.
Special Precautions
Renal insufficiency; given to patients in pain may provoke a paradoxical excitatory reaction, unless an analgesic is given concomitantly; drowsiness may persist the next day.
Adverse Reactions
Dependence; drowsiness, sedation, ataxia; resp depression; headache; GI disturbances; skin reactions; confusion and memory defects; paradoxical excitement, irritability; hypersensitivity reactions; haematologic disorders. Neonatal intoxication, vit K deficiency symptoms, congenital malformations (if taken during pregnancy). Nystagmus, miosis slurred speech and ataxia in excessive doses.
Drug Interactions
Sedation or resp depression may be enhanced by drugs with CNS depressants; MAOIs may prolong the CNS depressant effects and also reduce the convulsive threshold, thereby antagonise the anitconvulsant action of barbiturates. Others: Fenoprofen, methadone, pethidine and opioid analgesics; disopyramide, lidocaine and quinidine; chloramphenicol, doxycycline; warfarin and coumarin; antidepressants eg, bupropion, fluoxetine, lithium and mianserin; valproate and progabide; vigabatrin, oxcarbazepine, carbamazepine, clonazepam, ethosuximide, lamotrigine, tiagabine and zonisamide, griseofulvin; teniposide; metronidazole; chlorpromazine; HIV-protease inhibitors; β-blockers; calcium-channel blockers eg, nifedipine and verapamil; digitoxin; ciclosporin; corticosteroids; furosemide; montelukast; oral contraceptives; theophylline; levothyroxine; influenza vaccination and vitamins. Alcohol. St. John's wort.
Description: Allobarbital has general properties similar to amobarbital. It was formerly used in combination prep for the treatment of sleep disorders and pain, but barbiturates are no longer considered appropriate for such purposes.
MIMS Class
Hypnotics & Sedatives
Disclaimer: This information is independently developed by MIMS based on Allobarbital from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in